Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Apr 01, 2024

SELL
$30.43 - $56.65 $187,844 - $349,700
-6,173 Closed
0 $0
Q3 2018

Apr 01, 2024

BUY
$46.46 - $68.49 $286,797 - $422,788
6,173 New
6,173 $376 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Azzad Asset Management Inc /Adv Portfolio

Follow Azzad Asset Management Inc /Adv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

News

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.